Go Pro
TSE:EDT

Spectral Medical Q4 2025 Earnings Report

Spectral Medical logo
C$1.17 -0.01 (-0.85%)
As of 10/2/2026 03:58 PM Eastern

Spectral Medical EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Medical Revenue Results

Actual Revenue
$0.38 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Medical Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, March 26, 2026
Conference Call Time
10:30AM ET

Earnings Documents

Spectral Medical Earnings Headlines

The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
See More Spectral Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Medical and other key companies, straight to your email.

About Spectral Medical

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

View Spectral Medical Profile